ArticleAntibiotics (Basel, Switzerland)2022
Characterization of Carbapenem-Resistant
Article in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevalence of genes encoding carbapenem-resistance in Klebsiella pneumoniae recovered from clinical samples in Africa: systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Colonization with Carbapenemase producing Enterobacterales (CPE) and associated alteration in microbiota composition in a tertiary care hospital in Egypt.BMC microbiology · 2026Article
- Article
- Are New β-Lactam/β-Lactamase Inhibitor Combinations Promising Against Carbapenem-ResistantPathogens (Basel, Switzerland) · 2025Article
- Synergistic combination of ceftazidime and avibactam with Aztreonam against MDR Klebsiella pneumoniae in ICU patients.Scientific reports · 2025Article
- Antibiotic Susceptibility Patterns and Virulence Profiles of Classical and HypervirulentPathogens (Basel, Switzerland) · 2025Article
- Unveiling the potential of spirulina algal extract as promising antibacterial and antibiofilm agent against carbapenem-resistant Klebsiella pneumoniae: in vitro and in vivo study.Microbial cell factories · 2025Article
- Antimicrobial resistance and real-time PCR detection ofFrontiers in antibiotics · 2025Article
- Genomic dynamics of high-risk carbapenem-resistant klebsiella pneumoniae clones carrying hypervirulence determinants in Egyptian clinical settings.BMC infectious diseases · 2024Article
- Molecular characterization and epidemiological investigation of colistin resistance in carbapenem-resistant Klebsiella pneumoniae in a tertiary care hospital in Tehran, Iran.BMC microbiology · 2024Article
- Occurrence of carbapenem-resistant hypervirulent Klebsiella pneumoniae in oysters in Egypt: a significant public health issue.Annals of clinical microbiology and antimicrobials · 2024Article
- Phenotypic, molecular, and in silico characterization of coumarin as carbapenemase inhibitor to fight carbapenem-resistant Klebsiella pneumoniae.BMC microbiology · 2024Article
- Investigating the relationship between carbapenemase production and biofilm formation in Klebsiella pneumoniae clinical isolates.BMC research notes · 2024Article
- Molecular Typing and Drug Resistance Analysis of Carbapenem-resistant Klebsiella Pneumoniae from ICU Patients in China.Galen medical journal · 2024Article
- Emerging challenges in antimicrobial resistance: implications for pathogenic microorganisms, novel antibiotics, and their impact on sustainability.Frontiers in microbiology · 2024Review
- Emergence of pandrug-resistant carbapenemase-producingFrontiers in cellular and infection microbiology · 2024Article
- Genotyping and molecular investigation of plasmid-mediated carbapenem resistant clinicalAIMS microbiology · 2023Article
- Clinical carbapenem-resistantFrontiers in cellular and infection microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The advent of carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.